SEOUL, 27 March 2025 – PSI CRO AG, a global Swiss-based clinical research organization (CRO), has signed a Memorandum of Understanding (MOU) with Severance Hospital, one of South Korea’s most prestigious medical institutions. The two organizations will collaborate to support on-time delivery of pivotal clinical trials in South Korea.
Severance Hospital and PSI share a focus on supporting the development of specialized treatments in some of the most challenging therapeutic areas, including oncology, neurology, and gastroenterology. This strategic partnership harnesses PSI’s global expertise in clinical trial management and Severance Hospital’s world-class research capabilities to accelerate clinical development. This collaboration on clinical study feasibility will streamline patient recruitment through enhanced access to patient pools and data, ultimately improving enrollment timelines and trial quality.
“Through the signing of the MOU with PSI CRO Korea, we can further strengthen the international research capabilities of Severance Hospital and expand the research portfolio of our clinical trial center,” said Severance Hospital General Director Kang-Young Lee. “We will spare no effort to ensure that the clinical research conducted with PSI CRO Korea proceeds smoothly.”
Jin Seok Kim, Director of the Clinical Trial Center, added, “We expect this collaboration to generate powerful synergies by integrating Severance’s outstanding clinical expertise with PSI CRO’s exceptional infrastructure and specialized knowledge.”
Both organizations will work closely to optimize patient recruitment, streamline regulatory processes, and enhance data quality in clinical studies conducted in South Korea by sponsors around the globe.
This partnership highlights PSI’s dedication to expanding its presence in Asia and fostering strong relationships with top medical institutions to advance clinical research excellence. Recently, PSI has strengthened its service offerings across the Asia-Pacific region with key operational hubs in China, Taiwan, Thailand, Singapore, Australia, and New Zealand.
“This MOU marks the beginning of a powerful collaboration between two leaders in innovation and clinical excellence,” said PSI Head of Asia-Pacific Barrie Koh. “Together, we are not just signing an agreement — we are committing to a shared mission of advancing healthcare, transforming patient outcomes, and shaping the future of clinical research in Korea.”
From Left to right: Choi, Yoonjeong, Clinical Operations Manager at PSI CRO; Jegal, Sooyoun, Clinical Operations Manager at PSI CRO; Barrie Koh, Head of Asia Pacific at PSI CRO, Jin Seok Kim, Director, Clinical Trial Center at Severance Hospital; Choon Ok Kim, Associate Professor, Clinical Pharmacology department in Clinical Research Center; Hye Yong Lee, Manager, Clinical Trials Center; Wonseok Ryu, Team Leader of the Office for Clinical Research
About Severance Hospital
Established in 1885, Severance Hospital has become a recognized medical institution both in Korea and internationally, providing the highest level of care to patients with its outstanding medical staff and state-of-the-art facilities. The hospital actively conducts various clinical trials, and the results of these studies have been published in numerous international journals, attracting global attention. Severance Hospital particularly excels in the fields of cancer research and neuroscience, applying the latest medical technologies and research findings to patient care. The hospital offers specialized treatments in several areas, including oncology, cardiology, neuroscience, and gastroenterology. By continuously reflecting the latest research trends in each specialty, Severance Hospital is committed to developing new treatment methods and achieving the best possible outcomes through personalized care for patients. The hospital prioritizes the health and safety of its patients and will continue to maintain its leadership in the medical field through ongoing advancements.
About PSI
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2024.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI is celebrating its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,000 people across 56 countries as of December 31, 2024. Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
Additional Resources:
Strategic alliance: PSI CRO joins forces with Seoul’s Severance Hospital
For Media Inquiries
Paul Mirek
